Thousand Oaks biotech giant Amgen announced Sept. 24 that its leukemia treatment Blincyto had received approval from Japanese regulators. The drug is the first approval for the Japanese joint venture Amgen Astellas BioPharma and uses the company’s bi-specific T cell engager, or BiTE platform, which helps the body’s immune system target cancer cells. Blincyto has…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
